Adicet Bio, Inc.

Adicet Bio, Inc.

ACET·NASDAQ

$8.15

+4.1%
HealthcareBiotechnology

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.

At a Glance

Live Snapshot
Market Cap$76.19M
EPS-16.9500
P/E Ratio-0.48
Earnings Date08/06/2026

acet

Total Debt

Last Annual Value

14.74M

3-Year CAGR

-11%

5-Year CAGR

-7%

10-Year CAGR

-18%

Adicet Bio, Inc.

Adicet Bio, Inc. Competitors Analysis of Total Debt

ACET · NASDAQ
CompanyTotal Debt
CAGR 3Y
CAGR 5Y
CAGR 10Y
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
14.74M
-11.0%-6.8%-18.8% 
732.07K
-10.7%-14.6%N/A
0.00
N/AN/AN/A
91.70M
7.4%-2.3%N/A
5.22M
-32.8%47.7%N/A
61.65M
-45.2%-27.3%N/A
IMA logo
ImageneBio Inc
NASDAQ:IMA
9.99M
-2.4%7.4%N/A
29.11M
36.8%32.3%N/A
1.58M
-27.8%N/AN/A
94.14M
0.6%73.2%N/A
2.71M
-16.4%-13.6%N/A
Adicet Bio, Inc.

Adicet Bio, Inc. Fair Value Envelope

ACET · NASDAQ

Our analysis suggests that ACET has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $8.15, this represents a potential HIDDEN relative to our calculated worth for Adicet Bio, Inc..

Intrinsic Value
Current Price: $8.15